Drug Approval | July 04, 2023
Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Subscribe To Our Newsletter & Stay Updated
